CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project focuses on developing new therapeutic targets for non-small cell lung cancer by investigating the role of endothelial cells in tumor progression. By utilizing advanced genetic techniques, it aims to identify and validate novel immunosuppressive genes that can be targeted to enhance anti-tumor immune respons…
In non-small cell lung cancer (NSCLC), approximately 80% of patients have a poor response or develop resistance to current immunotherapies (IT), highlighting a critical need for more effective treatments.
To date, most ITs focus on targeting cancer or immune cells, often overlooking endothelial cells (ECs), the body's largest organ.
In the running ERC Adv Grant project MystIMEC (#101055155), we demonstrated the immunosuppressive nature of tumor ECs and their pathobiological role in tumor progres…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
